Reduces elevated serum total and LDL-C. ANDA 77510, held by Impax Labs. Colestipol Hydrochloride.
As of Nov 16, 2026, ANDA 77510 (Colestipol Hydrochloride), held by Impax Labs, was first approved by FDA on Oct 24, 2006, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 24, 2006 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colestipol Hydrochloride1GM · tablet;oral | Colestipol Hydrochloride | Rx |
| Apr 15, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 15, 2026 | Supplement 28Labeling · Standard review | Approved | None posted |
| Apr 15, 2026 | Supplement 31Labeling · Standard review | Approved | None posted |
| Oct 9, 2014 | Supplement 8Manufacturing | Approved | None posted |
| Oct 24, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters